All In Biotech

Drug Trial Radar · NCT00146770

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

A Multicenter, Multinational, Open-Label Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I

Last checked: Nov 20, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

45

Actual

Start

May 2001

Primary completion

Mar 2005

Study completion Mar 2005

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
BioMarin/Genzyme LLC
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.

Conditions

  • Mucopolysaccharidosis I
  • Hurler's Syndrome
  • Hurler-Scheie Syndrome
  • Scheie Syndrome

Interventions

  • AldurazymeBiological

    Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks

  • AldurazymeBiological

    0.58 mg/kg Aldurazyme every week for 208 weeks

  • placeboBiological

    Placebo for 26 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 182 in Percent Predicted Forced Vital Capacity (FVC)Time frame: Baseline to Week 182
  2. Change From Baseline to Week 182 in Six Minute Walk Test (6MWT)Time frame: Baseline to Week 182

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • University of South Alabama

    Mobile, Alabama

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Rochester

    Rochester, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Toledo Children's Hospital

    Toledo, Ohio

  • Merle West Medical Center

    Klamath Falls, Oregon

  • The Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Hospital Universatario de Universidade Federal de Santa Catarina

    Florianópolis, Brazil

  • Hospital Infantil Joana de Gusmao

    Florianópolis, Brazil

  • Alberta Children's Hospital

    Calgary, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Children's Hospital Klinikum Nord Heidberg

    Hamburg, Germany

  • Medizinishe Hochshule Hannover

    Hanover, Germany

  • Children's Hospital at the University Hospital of Heidelberg

    Heidelberg, Germany

  • Children's Hospital Klinikum der F.S. Universitat

    Jena, Germany

  • Catholic University Sacro Cuore

    Rome, Italy

  • Academisch Ziekenhuis Rotterdam

    Rotterdam, Netherlands

  • Belfast City Hospital

    Belfast, United Kingdom

  • Birmingham Children's Hospital

    Birmingham, United Kingdom

  • Bristol Royal Hospital for Children and Frenchay Hospital

    Bristol, United Kingdom

  • Gartnavel Hospital

    Glasgow, United Kingdom

  • Great Ormond Street Hospital for Sick Children and NHS Trust

    London, United Kingdom

  • Royal Victoria Hospital

    Newcastle upon Tyne, United Kingdom

  • Blackpool Victoria Hospital

    Blackpool, Lancashire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.